BridgeBio Oncology Therapeutics Inc. cash flow to debt ratio of -4.12K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BridgeBio Oncology Therapeutics Inc.'s free cash flow has decreased 14.89K% from $-763.82K last year to $-114.50M, signaling decreasing performance

BridgeBio Oncology Therapeutics Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

BridgeBio Oncology Therapeutics Inc. has insufficient data to evaluate this check.

BridgeBio Oncology Therapeutics Inc. has a net cash position, so leverage is healthy.

BridgeBio Oncology Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BridgeBio Oncology Therapeutics Inc. has insufficient data to evaluate this check.

BridgeBio Oncology Therapeutics Inc.'s short-term assets of $425.46M exceed its short-term liabilities of $35.04M

BridgeBio Oncology Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BridgeBio Oncology Therapeutics Inc.'s return on equity of -61.49%, is lower than 15.00%, indicating bad performance

BridgeBio Oncology Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BridgeBio Oncology Therapeutics Inc. has insufficient public price history to evaluate earnings stability.

BridgeBio Oncology Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BridgeBio Oncology Therapeutics Inc. has negative free cash flow, indicating cash burn

BridgeBio Oncology Therapeutics Inc.'s yearly earnings has decreased 80.47% since last year from $-74.28M to $-134.04M, signaling decreasing performance

BridgeBio Oncology Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -45.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BridgeBio Oncology Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

BridgeBio Oncology Therapeutics Inc. has insufficient public price history to evaluate revenue consistency.

BridgeBio Oncology Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.

BridgeBio Oncology Therapeutics Inc. has insufficient data to evaluate this check.

BridgeBio Oncology Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BridgeBio Oncology Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BridgeBio Oncology Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BridgeBio Oncology Therapeutics Inc. has insufficient data to evaluate this check.

BridgeBio Oncology Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BridgeBio Oncology Therapeutics Inc. has a price-to-book ratio of 0.78x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BridgeBio Oncology Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue